ObjectiveTo summarize the clinical efficacy of modified Morrow surgery in the treatment of hypertrophic obstructive cardiomyopathy. MethodsA retrospective analysis was conducted on the clinical data of patients with hypertrophic obstructive cardiomyopathy treated with modified Morrow surgery at Zhongshan Hospital Affiliated to Fudan University from 2020 to 2023. ResultsA total of 318 patients were enrolled, including 156 males and 162 females, with an average age of 55.6±13.1 years. Preoperative echocardiography showed a mean interventricular septal thickness of 18.1±3.8 cm, peak left ventricular outflow tract pressure difference of 86.4±24.9 mm Hg. The surgery time was 162.3±51.0 min, extracorporeal circulation time was 80.9±31.0 min, and aortic occlusion time was 44.8±20.8 min. After the surgery, transesophageal echocardiography showed that the interventricular septal thickness was 11.0±1.8 cm and left ventricular outflow tract peak pressure difference was 9.4±5.1 mm Hg. The incidence rate of postoperative complete left bundle branch block was 45.3%, Ⅲ° atrioventricular block was 3.8%, and postoperative newly developed atrial fibrillation was 3.1%. The postoperative hospital stay was 6.6±4.9 days, and one perioperative death occurred, with a mortality rate of 0.3%. The follow-up time was10.3±9.4 months, during which the transthoracic echocardiography revealed a ventricular septal thickness of 12.9±2.9 cm and a peak left ventricular outflow tract pressure difference of 13.9±10.0 mm Hg. ConclusionThe modified Morrow procedure for the treatment of hypertrophic obstructive cardiomyopathy is safe and effective, with good results in the short and medium term.